BGMS — Bio Green Med Solution Share News
0.000.00%
Last trade - 00:00- $5.02m
- $1.68m
- $0.75m
Brief: Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting
Cyclacel Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Cyclacel Pharmaceuticals Inc expected to post a loss of $4.74 a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of $4.74 a share - Earnings Preview
Brief: Cyclacel Pharmaceuticals Inc Files For Resale Of Up To 15.2 Million Shares By The Selling Stockholders
Brief: Cyclacel Pharmaceuticals Says Board Passed A Resolution To Suspend Payment Of quarterly dividend On Preferred Stock Scheduled For May 1, 2024
Cyclacel Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Cyclacel Pharmaceuticals Inc expected to post a loss of $5.89 a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of $5.89 a share - Earnings Preview
Brief: Cyclacel Pharmaceuticals Announces Reverse Stock Split
Brief: Cyclacel Receives Notification Of Deficiency From Nasdaq Regarding Timely Filing Of Quarterly Report
Brief: Cyclacel Q3 Net Income USD -6.097 Million
Cyclacel Pharmaceuticals Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Cyclacel Q2 basic EPS USD -0.44
Cyclacel Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Cyclacel Pharmaceuticals Inc expected to post a loss of 50 cents a share - Earnings Preview
Cyclacel Pharmaceuticals Inc expected to post a loss of 50 cents a share - Earnings Preview
Brief: Cyclacel Pharma Got Letter Notifying That Nasdaq Has Granted Co Until Jan 2, 2024 To Regain Compliance With Minimum Bid Price Rule
Cyclacel Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary